AxoGen (AXGN)
(Delayed Data from NSDQ)
$14.08 USD
-0.59 (-4.02%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $14.09 +0.01 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AXGN 14.08 -0.59(-4.02%)
Will AXGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXGN
Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?
BiomX Stock Gains From Favorable Study Data Presentation on BX004
AXGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
DGX Stock to Benefit From New Partnership With Sentara Health Plans
VERO Stock Likely to Get Support From New Regulatory Nod in Australia
Other News for AXGN
AxoGen: An Intriguing Growth Story
Axogen Inc (AXGN) Shares Up 2.8% on Sep 17
ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc
AxoGen completes submission of BLA to U.S. FDA for Avance Nerve Graft
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft?